No retraction, correction or concern found when last checked on Oct 17, 2026.

SARS-CoV-2 M pro inhibitors with antiviral activity in a transgenic mouse model

Jingxin Qiao, Yue-Shan Li, Rui Zeng and 40 more

Science · 2021 · CC BY

Abstract

Targeting the SARS-CoV-2 main protease Vaccines are an important tool in the fight against COVID-19, but developing antiviral drugs is also a high priority, especially with the rise of variants that may partially evade vaccines. The viral protein main protease is required for cleaving precursor polyproteins into functional viral proteins. This essential function makes it a key drug target. Qiao et al. designed 32 inhibitors based on either boceprevir or telaprevir, both of which are protease inhibitors approved to treat hepatitis C virus. Six compounds protected cells from viral infection with high potency, and two of these were selected for in vivo studies based on pharmokinetic experiments. Both showed strong antiviral activity in a mouse model. Science , this issue p. 1374

References 41

1.
A pneumonia outbreak associated with a new coronavirus of probable bat origin · 2020
No notice
2.
A new coronavirus associated with human respiratory disease in China · 2020
Corrected
3.
The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 · 2020
No notice
4.
P. Smith, Covid-19 in Australia: Most infected health workers in Victoria’s second wave acquired virus at work. BMJ 370, m3350 (2020 ).
Not in our library10.1136/bmj.m3350
5.
M.-K. Looi, Covid-19: Is a second wave hitting Europe? BMJ 371, m4113 (2020 ).
Not in our library10.1136/bmj.m4113
6.
Y. Chen, Q. Liu, D. Guo, Emerging coronaviruses: Genome structure, replication, and pathogenesis. J. Med. Virol. 92, 418–423 (2020 ).
Not in our library10.1002/jmv.25681
7.
R. Hilgenfeld, From SARS to MERS: Crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J. 281, 4085–4096 (2014 ).
Not in our library10.1111/febs.12936
8.
K. Anand, J. Ziebuhr, P. Wadhwani, J. R. Mesters, R. Hilgenfeld, Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs. Science 300, 1763–1767 (2003 ).
Not in our library10.1126/science.1085658
9.
L. Zhang, D. Lin, Y. Kusov, Y. Nian, Q. Ma, J. Wang, A. von Brunn, P. Leyssen, K. Lanko, J. Neyts, A. de Wilde, E. J. Snijder, H. Liu, R. Hilgenfeld, α-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: Structure-based design, synthesis, and activity assessment. J. Med. Chem. 63, 4562–4578 (2020 ).
Not in our library10.1021/acs.jmedchem.9b01828
10.
T. Pillaiyar, M. Manickam, V. Namasivayam, Y. Hayashi, S.-H. Jung, An overview of severe acute respiratory syndrome–coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small molecule chemotherapy. J. Med. Chem. 59, 6595–6628 (2016 ).
Not in our library10.1021/acs.jmedchem.5b01461
11.
Z. Jin, X. Du, Y. Xu, Y. Deng, M. Liu, Y. Zhao, B. Zhang, X. Li, L. Zhang, C. Peng, Y. Duan, J. Yu, L. Wang, K. Yang, F. Liu, R. Jiang, X. Yang, T. You, X. Liu, X. Yang, F. Bai, H. Liu, X. Liu, L. W. Guddat, W. Xu, G. Xiao, C. Qin, Z. Shi, H. Jiang, Z. Rao, H. Yang, Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 582, 289–293 (2020 ).
Not in our library10.1038/s41586-020-2223-y
12.
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors · 2020
No notice
13.
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease · 2020
No notice
14.
R. L. Hoffman, R. S. Kania, M. A. Brothers, J. F. Davies, R. A. Ferre, K. S. Gajiwala, M. He, R. J. Hogan, K. Kozminski, L. Y. Li, J. W. Lockner, J. Lou, M. T. Marra, L. J. Mitchell Jr.., B. W. Murray, J. A. Nieman, S. Noell, S. P. Planken, T. Rowe, K. Ryan, G. J. Smith 3rd, J. E. Solowiej, C. M. Steppan, B. Taggart, Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19. J. Med. Chem. 63, 12725–12747 (2020 ).
Not in our library10.1021/acs.jmedchem.0c01063
15.
B. Boras et al., Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19. bioRxiv [preprint]. 13 September 2020.293498
Not in our library
16.
M. Westberg et al., Rational design of a new class of protease inhibitors for the potential treatment of coronavirus diseases. bioRxiv [preprint]. 16 September 2020.275891
Not in our library
17.
C. Ma, M. D. Sacco, B. Hurst, J. A. Townsend, Y. Hu, T. Szeto, X. Zhang, B. Tarbet, M. T. Marty, Y. Chen, J. Wang, Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 30, 678–692 (2020 ).
Not in our library10.1038/s41422-020-0356-z
18.
M. D. Sacco, C. Ma, P. Lagarias, A. Gao, J. A. Townsend, X. Meng, P. Dube, X. Zhang, Y. Hu, N. Kitamura, B. Hurst, B. Tarbet, M. T. Marty, A. Kolocouris, Y. Xiang, Y. Chen, J. Wang, Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L. Sci. Adv. 6, eabe0751 (2020 ).
Not in our library10.1126/sciadv.abe0751
19.
W. Zhu, M. Xu, C. Z. Chen, H. Guo, M. Shen, X. Hu, P. Shinn, C. Klumpp-Thomas, S. G. Michael, W. Zheng, Identification of SARS-CoV-2 3CL protease inhibitors by a quantitative high-throughput screening. ACS Pharmacol. Transl. Sci. 3, 1008–1016 (2020 ).
Not in our library10.1021/acsptsci.0c00108
20.
K. S. Yang, X. R. Ma, Y. Ma, Y. R. Alugubelli, D. A. Scott, E. C. Vatansever, A. K. Drelich, B. Sankaran, Z. Z. Geng, L. R. Blankenship, H. E. Ward, Y. J. Sheng, J. C. Hsu, K. C. Kratch, B. Zhao, H. S. Hayatshahi, J. Liu, P. Li, C. A. Fierke, C. K. Tseng, S. Xu, W. R. Liu, A quick route to multiple highly potent SARS-CoV-2 main protease inhibitors. ChemMedChem 15, 1–8 (2020 ).
Not in our library10.1002/cmdc.202000924
21.
3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV–infected mice · 2020
No notice
22.
R. Cannalire, C. Cerchia, A. R. Beccari, F. S. Di Leva, V. Summa, Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: State of the art and future opportunities. J. Med. Chem. acs.jmedchem.0c01140 (2020 ).
Not in our library10.1021/acs.jmedchem.0c01140
23.
C. Gampe, V. A. Verma, Curse or cure? A perspective on the developability of aldehydes as active pharmaceutical ingredients. J. Med. Chem. 63, 14357–14381 (2020 ).
Not in our library10.1021/acs.jmedchem.0c01177
24.
P. S. Dragovich, T. J. Prins, R. Zhou, S. E. Webber, J. T. Marakovits, S. A. Fuhrman, A. K. Patick, D. A. Matthews, C. A. Lee, C. E. Ford, B. J. Burke, P. A. Rejto, T. F. Hendrickson, T. Tuntland, E. L. Brown, J. W. Meador 3rd, R. A. Ferre, J. E. V. Harr, M. B. Kosa, S. T. Worland, Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. J. Med. Chem. 42, 1213–1224 (1999 ).
Not in our library10.1021/jm9805384
25.
R. P. Jain, H. I. Pettersson, J. Zhang, K. D. Aull, P. D. Fortin, C. Huitema, L. D. Eltis, J. C. Parrish, M. N. G. James, D. S. Wishart, J. C. Vederas, Synthesis and evaluation of keto-glutamine analogues as potent inhibitors of severe acute respiratory syndrome 3CLpro. J. Med. Chem. 47, 6113–6116 (2004 ).
Not in our library10.1021/jm0494873
26.
Y. Yip, F. Victor, J. Lamar, R. Johnson, Q. M. Wang, D. Barket, J. Glass, L. Jin, L. Liu, D. Venable, M. Wakulchik, C. Xie, B. Heinz, E. Villarreal, J. Colacino, N. Yumibe, M. Tebbe, J. Munroe, S.-H. Chen, Discovery of a novel bicycloproline P2 bearing peptidyl α-ketoamide LY514962 as HCV protease inhibitor. Bioorg. Med. Chem. Lett. 14, 251–256 (2004 ).
Not in our library10.1016/j.bmcl.2003.09.074
27.
H. K. Ganguly, G. Basu, Conformational landscape of substituted prolines. Biophys. Rev. 12, 25–39 (2020 ).
Not in our library10.1007/s12551-020-00621-8
28.
P. Bazzini, C. G. Wermuth, in The Practice of Medicinal Chemistry, C. G. Wermuth, D. Aldous, P. Raboisson, D. Rognan, Eds. (Academic Press, ed. 4, 2015), pp. 319–357.
Not in our library
29.
Y. C. Martin, A bioavailability score. J. Med. Chem. 48, 3164–3170 (2005 ).
Not in our library10.1021/jm0492002
30.
S.-H. Sun, Q. Chen, H.-J. Gu, G. Yang, Y.-X. Wang, X.-Y. Huang, S.-S. Liu, N.-N. Zhang, X.-F. Li, R. Xiong, Y. Guo, Y.-Q. Deng, W.-J. Huang, Q. Liu, Q.-M. Liu, Y.-L. Shen, Y. Zhou, X. Yang, T.-Y. Zhao, C.-F. Fan, Y.-S. Zhou, C.-F. Qin, Y.-C. Wang, A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe 28, 124–133.e4 (2020 ).
Not in our library10.1016/j.chom.2020.05.020
31.
M. S. Weiss, R. Hilgenfeld, On the use of the merging R factor as a quality indicator for X-ray data. J. Appl. Crystallogr. 30, 203–205 (1997 ).
Not in our library10.1107/s0021889897003907
32.
P. A. Karplus, K. Diederichs, Linking crystallographic model and data quality. Science 336, 1030–1033 (2012 ).
Not in our library10.1126/science.1218231
33.
MolProbity : all-atom structure validation for macromolecular crystallography · 2009
No notice
34.
XDS · 2010
No notice
35.
How good are my data and what is the resolution? · 2013
No notice
36.
A. Vagin, A. Teplyakov, Molecular replacement with MOLREP. Acta Crystallogr. D 66, 22–25 (2010 ).
Not in our library10.1107/s0907444909042589
37.
L. Zhu, S. George, M. F. Schmidt, S. I. Al-Gharabli, J. Rademann, R. Hilgenfeld, Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease. Antiviral Res. 92, 204–212 (2011 ).
Not in our library10.1016/j.antiviral.2011.08.001
38.
Features and development of Coot · 2010
No notice
39.
O. Kovalevskiy, R. A. Nicholls, F. Long, A. Carlon, G. N. Murshudov, Overview of refinement procedures within REFMAC5: Utilizing data from different sources. Acta Crystallogr. D 74, 215–227 (2018 ).
Not in our library10.1107/s2059798318000979
40.
G. Bricogne et al., BUSTER version 2.10.3 (Global Phasing Ltd., 2017).
Not in our library

All 41 references

Cited by papers we hold 9

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors · 2023
No notice
A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases · 2022
No notice
Potent Anti‐SARS‐CoV‐2 Efficacy of COVID‐19 Hyperimmune Globulin from Vaccine‐Immunized Plasma · 2022
Not checked
(+)-Usnic acid and its salts, inhibitors of SARS‐CoV‐2, identified by using in silico methods and in vitro assay · 2022
Not checked
Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2 · 2022
No notice
Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19 · 2022
No notice
The SARS‐CoV‐2 main protease (M pro ): Structure, function, and emerging therapies for COVID‐19 · 2022
No notice
Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease · 2021
No notice
X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease · 2021
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.